Currently, the following natural and synthetic Hsp90-targeting drugs, such as ansamycin and derivatives of purine, resorcinol, benzamide, and tricyclic imidapyridines have been described in several disease models such as cancer [reviewed in (145)]. This evidence concerns the gene HSP90AB1 and cancer.